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Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USADiabeticnephropathy (DN) is themajor reason for end-stage renal disease in theWesternworld. Patientswith
DN developed more severe cardiovascular complications with worse prognosis. In spite of tight blood
pressure and glucose control through applying angiotensin Ⅱ receptor antagonism, angiotensin receptor
inhibitors, and even direct renin inhibitors, the progression and development of DN has continued to
accelerate.Nuclear receptorsare,with fewexceptions, ligand-depended transcription factors, someofwhich
modulate genes involved in the transport andmetabolism of carbohydrates or lipids, and in themodulation
of inﬂammation. Considering the diverse biological functions of nuclear receptors, efforts have been made
to explore their contributions to the pathogenesis of DN and their potential in therapeutic strategies. This
review is mainly focused on the association between various nuclear receptors and the pathogenesis of
DN, the potential beneﬁcial effects of targeting these receptors for treating and preventing the progress of
DN, and the important role that nuclear receptors may play in future therapeutic strategies for DN.
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Diabetic nephropathy (DN) develops in as many as
25% to 40% of diabetic patients after 25 years of un-
controlled and even treated diabetes. This makes DN the
leading reason for the development of late-stage renal
disease especially in the Western world2 where it
accounts for approximately 22% of patients starting
dialysis in Denmark3 and 44% in the USA.4 DN is
characterized clinically by the increased blood pressure,
occurrence of albuminuria, and a continual decrease of
kidney function,2 and is associated with a remarkable
increase in cardiovascular diseases5 and mortality.6 The
annual mortality rate for patients with DN-induced
renal disease is around 20%.7 During the last decade,
there has been an 11-fold increase in spending for the
treatment of patients with diabetes mellitus with
concomitant DN and chronic kidney disease in the USA.8
The diffuse thickening of glomerular basement
membrane together with nodular glomerulosclerosis is
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International Reports (2016) 1, 177–188stage of diabetic kidney disease, most patients only
present modest proteinuria that deteriorates as the
disease progresses. More advanced DN leads to primary
and secondary pathological changes in the tubu-
lointerstitial and vascular compartments, which is
harmful to the maintenance of renal function. In a
proportion of patients with clinical symptoms of DN,
additional primary renal diseases (e.g., IgA nephropa-
thy and renal arterial disease) may result from the
diabetes mellitus-driven pathological abnormalities.
Although the pathophysiology of DN is mainly due to
hyperglycemia, it is also related to the wider network
involving local and systemic processes,9,10 some of
which have been identiﬁed with cell and animal
models, tissue samples, and human studies. For
instance, in renal parenchymal cells, hyperglycemia
induces abnormal activation of protein kinase C
together with the increased expression of transforming
growth factor b (TGFb), matrix proteins ﬁbronectin
and collagen type IV, the dysregulation of nitric oxide,
endothelial dysfunction and activation of the nuclear
factor kappa B, and mitogen-activated protein kinase
signaling.10–12 In addition, hyperglycemia can result in
the overproduction of advanced glycation end prod-
ucts and induce overexpression of TGFb.13 In spite of
certain available treatments, the progression of DN
continues to increase worldwide and thus novel ther-
apeutic strategies are urgently needed.177
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various roles in embryo development, maintenance of
the differentiated cellular phenotype, and manipulation
of cell metabolism and death. This review mainly
discusses the association between the pathogenesis
of DN and nuclear receptors, including peroxisome
proliferator–activated receptors (PPARs) a (NR1C1),
b/d (NR1C2), and g (NR1C3); farnesoid X receptor (FXR,
NR1H4); liver X receptors (LXRs, NR1H2, NR1H3);
vitamin D receptor (VDR, NR1I1); hepatocyte nuclear
factor 4a (HNF4a, NR2A1); retinoid X receptors
(RXR, NR1F1, NR1F2, NR1F3); retinoid acid receptors
(NR1B1, NR1B2, NR1B3); estrogen receptor (ER,
NR3A1); and mineralocorticoid receptor (MR, NR3C2).
Several studies have suggested that activation or inhi-
bition of speciﬁc receptors could prevent the progres-
sion of DN, which implies that targeting nuclear
receptors may be a potential therapeutic strategy
for DN.
Nuclear Receptors
PPAR
PPARs are ligand-activated transcriptional factors and
include 3 related forms PPARa, PPARb/d, and PPARg.
Although they all have different tissue distributions,
ligand selectivities, and biological effects, they play an
important role in modulating lipid metabolism, adipo-
genesis, insulin sensitivity, inﬂammation, and blood
pressure. Renal PPARa and PPARg modulate energy
utilization in the kidney by regulating fatty acid
oxidation.14 Activated PPARa can stimulate fatty acid
b-oxidation that can reduce the lipid content of tissues
and blood, prevent the accumulation of lipid, and
ameliorate lipotoxicity.15 Several kinases, including
protein kinase A, protein kinase C, mitogen-activated
protein kinases, and adenosine monophosphate
kinase, were shown to phosphorylate PPARs resulting
in changes in DNA-binding activity, ligand afﬁnity,
recruitment of transcriptional cofactors, and protea-
some degradation in both a ligand-dependent or
-independent manner.16 Phosphorylation by adenosine
monophosphate kinase leads to increased PPARa and
PPARg signaling and enhances renal function in a type
2 diabetes mouse model by removing lipid accumula-
tion in the kidney.15 Furthermore, the activation of
PPARg suppresses the renal expression of an
a(1D)-adrenergic receptor that is overexpressed in the
diabetic kidney.17
Chronic inﬂammation and oxidative stress play a
pivotal role in the pathogenesis of chronic kidney
disease. Activated PPARa can prevent overexpression
of proinﬂammatory molecules.18 It was shown that the
ligand activation of PPARa will increase the expression
of ﬁbroblast growth factor-21 (FGF-21), enhance the178phosphatidylinositol-3 kinase/protein kinase B (AKT)/
glycogen synthase kinase 3b (GSK-3b)/Fyn-mediated nu-
clear factor (erythroid-derived 2)-like 2 signal, and
prevent the development of DN.19 PPARa activation
improves lipotoxicity by activating adenosine mono-
phosphate kinase-peroxisome proliferator-activated
receptor g coactivator-1a (PGC-1a)-estrogen-related
receptor-1a (ERR-1a)-forkhead box 03a (Fox03a)
signaling and ameliorating glucose-induced matrix
production and mesangial cell proliferation by inhibit-
ing extracellular signal–regulated kinase 1/2 and phos-
phatidylinositol-30-kinase/AKT activation, suggesting
its potential for the treatment of DN.20,21 In the absence
of PPARa, the glomerular lesions displayed enhanced
type IV collagen and TGFb levels in DN, indicating that
PPARa agonists can prevent glomerular matrix expan-
sion together with apoptosis and the inﬁltration of in-
ﬂammatory cells within the glomerulus.22 A recent
study found that Huangkui capsule, an extract from
Abelmoschus manihot (L.) medic, can ameliorate DN by
increasing PPARa/PPARg signaling leading to lowered
endoplasmic reticulum (ER) stress in rats.23 It was re-
ported that fenoﬁbrate, a PPARa agonist, can dramati-
cally decrease the excretion of urinary albumin and
reduce mesangial matrix expansion and glomerular
hypertrophy in the db/db diabetic mice model.24 Feno-
ﬁbrate also improved insulin resistance and glomerular
lesions in db/db mice,24 thus suggesting a renal protec-
tive role for fenoﬁbrate in DN via the activation of
PPARa in mesangial cells. A Fenoﬁbrate Intervention
and Event Lowering in Diabetes study further sug-
gested that the early use of fenoﬁbrate may prevent or
postpone the development of DN.25
The protection provided by activated PPARg is
partially mediated by downregulating the level of renal
disintegrin and metalloprotease-17 (ADAM17) and
angiotensin-converting enzyme-2 (ACE2) shedding.26
Increased ﬁbrosis in glomerular microenvironment is
a remarkable characteristic of DN. Strong evidence
suggests that PPARg plays an important role during
the pathogenesis of glomerulosclerosis. Treatment with
PPARg agonist ameliorated the hyperglycemia-
mediated cannabinoid receptor type 1 (CB1R)
signaling, inﬂammation, and glomerular ﬁbrosis in
diabetic animals.27,28 PPARg could prevent protein
kinase A signaling, the activation of rat intraglomerular
mesangial cells, TGFb-induced accumulation of
p-cyclic-AMP-responsive element binding protein and
collagen-IV.29 PPARg also negatively regulates
inﬂammation through binding to the MIP3A promoter
and downregulating the expression of macrophage in-
ﬂammatory protein-3a (MIP-3a), a pathogenic mediator
playing a crucial role in inﬂammation of DN.30 Other
studies showed that PPARg provides renoprotectiveKidney International Reports (2016) 1, 177–188
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prostaglandin E synthase-1 (mPGES-1)/prostaglandin
E2/prostaglandin E2 receptor 4 (EP4) pathway and
restoring expression of the klotho axis in a PPARg-
dependent manner.31,32 PPARg may enhance the
function of the angiotensin II receptor blocker by
downregulating thioredoxin-interacting protein.33
PPARg activated by pigment epithelium-derived fac-
tor could suppress the expression of the receptor for
advanced glycation end products and decrease the
reactive oxygen species (ROS), which subsequently
prevents advanced glycation end product-induced
apoptotic cell death in podocytes.34 Many studies
were performed to separate the insulin sensitizing ef-
fects of PPARg agonists from the transcriptional acti-
vation of genes that result in untoward side effects.
This was achieved to some degree by using partial
agonists that, compared with a full agonist, only
partially activated the transcription of select genes.35
Among patients with type 2 diabetes, the poly-
morphism within PPARg2 (Pro12Ala) provides protec-
tion against nephropathy progression and deterioration
of renal function, independent of major confounders.36
However, the PPARg2 (Pro12Ala) polymorphism may
not be associated with the progression of DN in patients
with type 1 diabetes.37 A meta-analysis showed that the
PPARg (Pro/Pro) genotype presented close association
with DN risk in Caucasians, but the Ala/Ala genotype
and Ala allele did not.38 Conversely, another meta-
analysis indicated that the polymorphism in PPARg
(Pro12Ala) gene has no relationship with DN risk in
Asians.39 The rs1801282 C>G variant in PPARg was
closely associated with decreased DN risk.40 However,
further studies revealed that the PPARg2 Ala12 variant
provided renal protection by reducing the occurrence of
albuminuria among patients with type 2 diabetes.41,42
PPARb/d agonist treatment inhibited glomerular
mesangial expansion, albuminuria, and the accumulation
of type IV collagenwith no effect on blood glucose levels
in streptozotocin-treated diabetic mice.43 The activation
of PPARb/d is necessary for treating DN by preventing
inﬂammation and activating of its downstream receptor
for advanced glycation end product or nuclear factor
kappa B signals.43,44 PPARb/d agonist could postpone
diabetes-induced nephrin loss, enhance podocyte
integrity, and prevent albuminuria subsequently.45
LXR
LXRs were ﬁrst identiﬁed as orphan receptors when
discovered, and then subsequently found to be targets of
oxysterolmetabolites of cholesterol.46 LXRs include LXRa
and LXRb that have different tissue distribution patterns,
but have beenmost extensively studied in the liver. LXRs
might have a role in regulating lipid metabolism andKidney International Reports (2016) 1, 177–188maintaining the function of proximal tubule as well as
podocytes by downregulating the expression of neph-
rin.47 The administration of the LXR agonist T0901317
could increase cholesterol efﬂux via activating the ATP-
binding cassette transporter A1 (ABCA1) in cultured
glomerularmesangial cells, and enhance the expression of
stearoyl-CoA desaturase-1 through increasing the level of
sterol regulatory element-binding protein 1c (SREBP-1c)
within proximal tubules.48,49 LXRa/SREBP-1 signaling
also has the capability of regulating the expression of
many genes involved in fatty acid and triglyceride syn-
thesis.50 Nε-(carboxymethyl) lysine, a member of the
advanced glycation end product family, modulates
cholesterol metabolism through stimulating LXR and
SREBP-2, which resulted in a reduction in ABCA1-
mediated cholesterol efﬂux and the accumulation of lipid
in human kidney-2 (HK-2) cells.51 Bilirubin improved
dyslipidemia and renal disfunction via suppressing the
expression of LXRa and SREBP-1 and decreasing ROS.52
Furthermore, the activation of LXR may prevent inﬂam-
mation and the development of DN.46,53 T0901317 could
prevent the development of albuminuria, glomerular
mesangial expansion, and interstitialﬁbrosis bydecreasing
osteopontin level, macrophage inﬁltration, and expression
of inﬂammatory genes, such as monocyte chemoattractant
protein-1 (MCP-1), tumor necrosis factor a (TNFa), and
TGFb, in the diabetic kidney.46 Knockdown of LXRa
expression resulted in loss of the anti-inﬂammatory effect
of anthocyanins, and further studies demonstrated that
LXRa might participate in the anthocyanin-induced
action of decreasing intercellular adhesion molecule 1,
MCP1, and TGFb1 via inhibiting the nuclear translocation
of nuclear factor kappa B protein.54 Expression of LXRa
in macrophage of transgenic mice markedly ameliorated
hyperlipidemic-hyperglycemic nephropathy by sup-
pressing glycated or acetylated low-density lipoprotein-
induced cytokines and ROS in macrophages.55 Recently,
accelerated mesangial matrix expansion and glomerular
lipid accumulation were observed in Lxra/Lxrb-null dia-
betic mice, in coupling with the enrichment of oxidative
stress and inﬂammatory markers. Moreover, treatment
with a synthetic oxysterol, N,N-dimethyl-3beta-hydrox-
ycholenamide, an LXR agonist, dramatically ameliorated
the excretion of albumin and nephrin, the levels of
glomerular lipids and plasma triacylglycerol and choles-
terol. In addition, the decreased level of kidney inﬂam-
matory and oxidative stress markers was observed upon
N,N-dimethyl-3beta-hydroxycholenamide treatment.47
Together, these results indicate that the activity of LXR
is necessary for both normal and diabetic kidney.
FXR
FXR was ﬁrst thought to be an orphan receptor when
discovered. However, further studies revealed that179
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bile-acid synthesis and transport in the liver and in-
testine.56–58 Endogenous ligands for FXR include the
primary bile acids, taurocholic acid, chenodeoxycholic
acid, and cholic acid. FXR is expressed at highest levels
in the liver and intestine, and at lower levels in adrenal
gland and other tissues; it is also highly expressed in the
kidney.59 It also plays a pivotal role in lipid, glucose, and
bile acid homeostasis in the enterohepatic system.60,61
Furthermore, FXR agonists may provide protection
against liver ﬁbrosis.62,63 FXR agonists downregulate
renal overexpression of SREBP-1 that could lead to lipid
accumulation during the development of nephropathy
and regulating renal lipid metabolism. The activation of
FXR could prevent the induction of proﬁbrotic growth
factors, proinﬂammatory cytokines, and oxidative
stress-related enzymes in the kidney, and thus improve
glomerulosclerosis and proteinuria.64 Furthermore, the
activation of FXR could suppress the development of
nephropathy in type 1 diabetes via blocking diabetes-
induced dysregulation of lipid metabolism, ﬁbrosis,
inﬂammation, and oxidative stress in the kidney.65
Recently, the adipocytokine visfatin was found to
have a crucial role in the development of DN, at least
partly, through enhancing high glucose-induced human
mesangial cell inﬂammation, ﬁbrosis, and proliferation
in the absence of FXR.66
VDR
Vitamin D is necessary for the metabolism of calcium
and bone. It was reported that vitamin D deﬁciency was
closely associated with increased risk for diabetes
development, diabetes complications, and cardiovascu-
lar disease.67 A meta-analysis including 5 observational
studies suggested that children treated with vitamin D
are less likely to develop type 1 diabetes mellitus.68 The
fact that the lack of vitamin D impairs insulin synthesis
and secretion suggested its close association with the
pathogenesis of type 2 diabetes, although the mecha-
nistic link has not been well established.69
The protective activities of VDR may result from the
inhibition of the renin-angiotensin system, reduction of
proteinuria, and regulation of cell proliferation and
differentiation. A recent study suggested that vitamin
D and its receptor might modulate the progression of
DN via regulating the TGFb levels, the expression of
angiotensinogen, and apoptosis of podocytes through
the nuclear factor kappa B pathway.70 Activated mac-
rophages 1 (M1) and activated macrophages 2 (M2)
have opposing roles in inﬂammation. M1 activation
was inhibited by 1,25-dihydroxyvitamin D3, a VDR
agonist, while M2 was activated.71 Another study re-
ported that vitamin D can switch the M1 phenotype to
M2 via activating the VDR-PPARg pathway.72 Diabetic180Vdr null mice developed more severe nephropathy than
wild-type mice as renin-angiotensin system activation
was enhanced, suggesting that VDR protects the kid-
ney from hyperglycemia-induced injury through
inhibiting renin-angiotensin system activity.73 These
data indicated that the combination of renin-
angiotensin system inhibitors and a VDR activator
might be of value to improve DN-induced albumin-
uria.74 A randomized clinical trial revealed that daily
treatment of paricalcitol, a selective VDR agonist, could
ameliorate residual albuminuria in ACE inhibitor
(ACEI)- or angiotensin II type 1 receptor blockade
(ARB)-treated DN patients, especially in those with
high dietary sodium intake. These data suggested that
the combination of paricalcitol and ACEI or ARBs could
effectively reduce residual albuminuria, which may be
applied as a new strategy in the treatment of DN.75
Wnt/b-catenin signal-related epithelial-mesenchymal
transition was reportedly involved in the pathogenesis
of DN.76 A recent study documented that VDR could
decrease the expression of b-catenin by replacing
b-catenin complexing with transcription factor 4
(TCF-4), therefore blocking Wnt/b-catenin signaling.77
Podocyte injury is one of the causes of DN.78 VDR
activation in podocytes plays an important role in
preventing the kidney from diabetic damage.79 Calci-
triol or a vitamin D analog can improve podocyte
damage by inhibiting the expression of transient re-
ceptor potential cation channel. subfamily C. member 6
(TRPC6) during the early stage of DN in a rat model.78
1,25-D3 treatment ameliorated proteinuria in
25-hydroxy-1a-hydroxylase conventional knockout
mice coupled with increasing heparanase expression,
suggesting that vitamin D mediated the emergence of
proteinuria by reducing heparanase levels in podo-
cytes.80 Furthermore, vitamin D analogs provide pro-
tection against lesion of renal barrier by maintaining
and reactivating the expression of podocalyxin, a
specialized component of podocytes.81
The anti-inﬂammatory action of vitamin D is due to
its inﬂuence on the crosstalk between signal transducer
and activator of transcription 5 and VDR.82 A functional
polymorphism of theVDR gene may result in individual
susceptibility to DN, and a meta-analysis suggested the
correlation of a Fok1 single-nucleotide polymorphism
with DN susceptibility in Caucasians.83 Another study
showed that a BsmI single-nucleotide polymorphism
polymorphism in Han Chinese people was responsible
for the type 2 diabetes-related albuminuria.84
MR
MR regulates the reabsorption of sodium and water and
secretion of potassium via control of the epithelial ion
channel. The representative agonist and antagonist ofKidney International Reports (2016) 1, 177–188
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However, mineralocorticoids could not only regulate
the transport of epithelial salt, extracellular volume,
and blood pressure, but also inﬂammation and ﬁbrosis
either directly or indirectly. Emerging evidence in-
dicates that aldosterone participates in the pathogenesis
of kidney disease in a nonepithelial MR-dependent
manner.85 Some studies also reported that aldosterone
impairs insulin sensitivity through MR activation in
adipocytes in vitro, which indicates that aldosterone
may play an important role in the development of
diabetes.86,87 Interestingly, leptin, which is upregu-
lated in diabetic obese models, stimulates aldosterone
production in vitro in human adrenocortical cells and
in vivo in mice. In addition, aldosterone increases
ﬁbrosis by upregulating the production of TGFb1,
ROS, plasminogen activator inhibitor 1 (PAI-1), and the
enrichment of collagen protein, which can be blocked
by MR antagonist.88 Integrin b1 and b3 expression in
podocytes is essential to the integrity of a glomerular
structure. In a high glucose environment, the expres-
sion of integrin b1 in cultured podocytes is markedly
decreased, accompanied with an increase of integrin
b3, and a recent study suggested that spironolactone
inhibited cell motility and stabilized podoctyes
cultured in a high glucose environment, in part by
normalizing the level of integrin b1 and b3.89 Treat-
ment with spironolactone provides protection for
podocytes and inhibits the development of morpho-
logical changes associated with DN, probably by the
inhibition of TGFb1 mRNA expression.90 Spi-
ronolactone could inhibit MR-induced ROS production
and hyperglycemia-mediated podocyte lesions in dia-
betics.91 Recent studies revealed a crucial role for
aldosterone in the pathogenesis of DN, which has no
effect on angiotensin II and blood pressure levels.92
Another study enrolling type 2 diabetic patients also
demonstrated that patients who developed aldosterone
escape, an increase in aldosterone levels during long-
term treatment of ACEIs, suffered more severe albu-
minuria than did patients without aldosterone escape.
However, in combination with spironolactone treat-
ment a further decrease in albuminuria was noted in
these patients.92 Furthermore, the incidence of severe
hyperkalemia, which is the major side effect of spi-
ronolactone treatment in clinical trials, is low, probably
resulting from the monitoring of dietary intake of po-
tassium and diuretics in clinical observation. However,
the liberalized usage of spironolactone is strictly
forbidden for patients whose kidney function was
reduced.92 It was suggested that alterations of Na/K
ATPase levels might be a new pathophysiological
feature for DN. The ability of aldosterone antagonists to
decrease Na/K ATPase protein levels and enzymeKidney International Reports (2016) 1, 177–188mislocation that are increased in diabetes may suggest a
new pharmaceutical use in the treatment of DN.93
Other Nuclear Receptors
The sex hormone estrogen has several functions
including control of bone growth, modulation of dif-
ferentiation and function of the reproductive tract, and
memory storage.94,95 Estrogen exerts its biological ac-
tivity through the interaction with classic estrogen re-
ceptors, ERa and ERb.96 It is generally known that
females have a lower chance of suffering from nondia-
betic chronic kidney disease than males.97–100 Although
the contribution of gender to the progression of type 1 or
type 2 diabetic renal disease is still uncertain,100,101 some
studies suggested that DN even progresses faster in
males than females.102–108 However, other results indi-
cated an acceleration of disease progression in
females,109–112 whereas some studies reported no dif-
ference between men and women.113–115 Because ERb
can regulate cell apoptosis and cycle in tumor cells116
and ERb protein expression is increased in podocytes
treated with estrogen,117 estrogens could protect against
podocytes apoptosis.117 The fact that podocytes isolated
from estrogen-treated diabetic mice showed an increase
in the level of AKT phosphorylation indicates that
estrogen may achieve such an effect by activating the
phosphatidylinositol-30-kinase-AKT axis.117 The
increased ERb protein level in podocytes could manip-
ulate the cell cycle and increase cell survival rates,
suggesting that estrogen has the capability of prevent-
ing podocyte loss during diabetes-mediated kidney
disease.117 Several lines of evidence revealed that TGFb
promotes diabetic kidney disease, at least partly through
inducing cell apoptosis and podocyte clearance.118–121
Relevant data showed that E2 treatment provides pro-
tection for podocytes against TGFb or (TNFa)-induced
apoptosis in vitro. Other studies suggested that treat-
ment with E2 could be helpful to prevent albuminuria,
glomerulosclerosis, and tubulointerstitial ﬁbrosis in the
initial stages of diabetes.122–124 However, some studies
did not support the protective effects of estrogens for
the patients with diabetic kidney. A recent study found
that elevated serum concentrations of phytoestrogens
are positively correlated with the severity of diabetic
renal disease, suggesting the potential harmful effect of
phytoestrogens.125
Retinoic acid is the active metabolite of vitamin A,
which plays a pivotal role in many physiological pro-
cesses including but not limited to energy metabolism.
Retinoic acid can facilitate the formation of retinoic acid
receptor/RXR heterodimers or RXR/RXR homodimers,
which could bind to the retinoic acid response element
upstream of retinoic acid target gene promoters and
modulate their transcription in the presence of speciﬁc181
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form heterodimers with RXR, and modulate the biolog-
ical function of several hormones and drugs.128,129 For
example, the RXRa:RXRa homodimer and RXRa:PPARg
are needed to recruit their coactivators to initiate the
transcription of target genes130 through binding to their
response elements.131 Considering that PPARg is a key
target in the treatment of DN, RXRa targeting may
become a new treatment strategy. Furthermore, RXRs
can be used as permissive heterodimers with LXR, FXR,
PXR, and constitutive androstane receptor (CAR), or as
nonpermissive heterodimer interacting with VDR,Table 1. Systematic and renal effects of nuclear hormone receptor activ
Nuclear hormone receptor
Affected genes, proteins, and
processes Ago
PPARa14,15,19–21 (highly expressed in
proximal tubule epithelium and
medullary thick ascending limbs,
with lower levels in glomerular
mesangial cells)
Fatty acid oxidation, NFkB, FGF21,
PI3K/Akt/GSK-3b/Fyn-Nrf2 signaling,
AMPK-PGC-1a-ERR-1a-FoxO3a
signaling, PI3K/AKT, and ERK1/2
signaling
Fib
PPARg14,15,26,27,29–34 (primarily
expressed in the epithelium of distal
medullary collecting ducts and to a
lesser extent in the glomerular
mesangial cells, endothelial cells
and podocytes, proximal tubular
cells, endothelial cells of renal
microvasculature, and interstitial
ﬁbroblast cells)
Renal disintegrin, metalloprotease-17,
angiotensin-converting enzyme-2,
CB1R signaling, protein kinase A,
pCREB, collagen-IV, MIP-3a,
mPGES-1/PGE2/EP4 pathway,
klotho axis, thioredoxin-interacting
protein, RAGE, ROS
Glita
PPARb/d14,17,43,44 (highly expressed
in medullary interstitial and stromal
cells)
a(1D)-adrenergic receptor, collagen-IV,
RAGE, NFkB
GW
LXR46,48–50,53,55 (expressed in all
major renal cells including
mesangial cells, endothelial cells,
and podocytes)
ABCA1, SREBP-1c, OPN, MCP-1,
TNFa, TGFb, ROS
T090
FXR56–58,64–66 (expressed in isolated
glomeruli and proximal tubules,
cultured mesangial cells, and
podocytes)
SREBP-1, visfatin Chenodeox
cho
VDR69,70,72,73,78,80–82,154–156
(expressed in the proximal and distal
tubular epithelial cells, glomerular
parietal epithelial cells, collecting
duct cells and cultured podocytes,
and mesangial cells)
VDR-PPARg pathway, TRPC6,
heparanase, podocalyxin, STAT5,
TGFb, angiotensinogen, NF-kB
1,25-Dihyd
D3,
MR85–93 (expressed in the ortical
collecting duct cells of distal
nephrons)
TGFb1, ROS, PAI-1, collagen, integrin
b1, integrin b3, NKA, ROS
Aldos
Estrogen receptors a and
b117,122–124,157–159 (expressed in
glomeruli, isolated mesangial cells
and podocytes)
PI3K-AKT signaling, TGFb, TNFa Estr
RXR131,137 (distribution unknown in
kidney)
PPAR, LXR, FXR, VDR Mag
HNF4a142–144 (distribution unknown in
kidney)
STIM1 N
ABCA1, ATP-binding cassette transporter A1; AKT, protein kinase B; AMPK, adenosine monoph
kinase; ERR, estrogen-related receptor; FGF, ﬁbroblast growth factor; FoxO3, forkhead box 03; F
macrophage inﬂammatory protein; NA, not available; Nrf2, nuclear factor (erythroid-derived 2)-l
AMP-responsive element binding protein; PGCg-1a, peroxisome proliferator-activated recepto
activated receptors; RAGE, receptor for advanced glycation end products; RAS, renin-angioten
protein 1c; STAT5, signal transducer and activator of transcription 5; STIM1, stromal interacting
transient receptor potential cation channel, subfamily C, member 6; VDR, vitamin D receptor.
182and as conditional heterodimers together with
retinoid acid receptor or thyroid receptor (TR).132 On the
other hand, because of the nature of its partners, the
activation state of RXR changes in different hetero-
dimers.133 Three RXR subtypes were identiﬁed as RXRa,
RXRb, and RXRg.134,135 As compared with the universal
distribution of RXRa and RXRb, RXRg is only detected
in some speciﬁc tissues.136 RXRa also showed antioxi-
dants properties and played an important role in the
pathogenesis of diabetic retinopathy.137 RXRg encoded
by RXRG gene was also involved in the pathogenesis
of DN.138ation in the context of diabetic nephropathy
nists
Outcomes of receptor
activation Mechanism of action
rates YMesangial expansion,
Ymatrix production,
Yproteinuria
Systemic: Yinsulin resistance, Ylipid,
Yhypertension
Renal: anti-inﬂammatory, antiﬁbrotic,
antiapoptotic properties
zones YProteinuria;
Yglomerulosclerosis,
Ytubulointerstitial ﬁbrosis
Systemic: Yinsulin resistance, Ylipid,
Yhypertension
Renal: anti-inﬂammatory, antiﬁbrotic,
antioxidative, antiapoptotic
properties
0742 YProteinuria, Ymesangial
expansion,
Ytubulointerstitial ﬁbrosis
Renal: anti-inﬂammatory, antiﬁbrotic
1317 YProteinuria, Ymesangial
expansion,
Ytubulointerstitial ﬁbrosis,
Ymacrophage inﬁltration in
kidney
Systemic: Ylipid
Renal: anti-inﬂammatory, antiﬁbrotic,
antioxidative
ycholic acid,
lic acid
YProteinuria,
Yglomerulosclerosis,
Ymesangial cell
inﬂammation, Ymesangial
expansion,
Ytubulointerstitial ﬁbrosis
Systemic: Ylipid
Renal: anti-inﬂammatory, antiﬁbrotic,
antioxidative
roxyvitamin
calcitriol
YProteinuria,
Yglomerulosclerosis,
Ymacrophage inﬁltration in
kidney
Systemic: Yinsulin resistance, YRAS
Renal: anti-inﬂammatory, antiﬁbrotic,
antiapoptotic
terone [Proteinuria, Yglomerular
structural integrity
Systemic: [hypertension, [insulin
resistance
Renal: inﬂammation, [ﬁbrosis,
[oxidation
ogen [Glomerular structural
integrity, Yprotenuria,
Yglomerulosclerosis,
Ytubulointerstitial ﬁbrosis
Renal: anti-inﬂammatory, antiﬁbrotic,
antiapoptotic properties
nolol NA Renal: antioxidative
A YGlomerulosclerosis Renal: antiﬁbrotic
osphate kinase; CB1R, cannabinoid receptor type 1; ERK, extracellular signal–regulated
XR, farnesoid X receptor; GSK, glycogen synthase kinase 3b; LXR, liver X receptor; MIP,
ike 2; NKA, Na/K ATPase; NF-kB, nuclear factor kB; OPN, osteopontin; pCREB, p-cyclic-
r g coactivator-1a; PI3K, phosphatidylinositol-30-kinase; PPAR, peroxisome proliferator–
sin system; ROS, reactive oxygen species; SREBP-1c, sterol regulatory element-binding
molecule-1;TGFb, transforming growth factor b; TNFa, tumor necrosis factor-a; TRCP6,
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HNF4a is expressed at high levels in the liver, kidney,
and intestine, and controls the expression of a large gene
set including those involved in glucose and fatty acid
metabolism, urea biosynthesis, cholesterol metabolism,
blood coagulation, hepatitis B virus infection, and he-
patocyte differentiation.139 Dysfunction of HNF4a can
lead to metabolic disease. Notably, genetic mutations in
HNF4a result in maturity-onset diabetes of the young-
1.140 The expression of the HNF4a gene is signiﬁcantly
decreased in the kidney and liver in 2 diabetic rodent
models.141Additionally, HNF4a is decreased in kidneys
of patients with DN. HNF4a negatively regulates the
transcription of stromal interacting molecule-1, which is
increased in a high glucose environment in mesangial
cells.142 Blockage of HNF4a in mesangial cells might be a
candidate therapeutic strategy for DN, as the stromal
interacting molecule-1-gated store-operated Ca(2þ) en-
try pathway in mesangial cells was recently found to be
antiﬁbrotic.142–144
HNF1a is a homeodomain-containing transcription
factor that plays an important role for modulating
different metabolic functions in the liver, pancreatic
islet, kidney, and intestine.145 Maturity-onset diabetes
of the young-3 result from rare mutations in
HNF1A.146,147 Although genetic variants in HNF1b are
not a major cause of maturity-onset diabetes of the
young or DN, they might lead to the manifestation of
disease in Chinese.148
Conclusion
The systematic and renal effects of nuclear hormone re-
ceptor activation in the context of diabetic nephropathy
are shown in Table 1. Among the highlights, the ﬁbrate
class of PPARa agonists have long been prescribed to
reduce triglyceride (TG), increase high-density lipo-
protein-C (HDL-C), and improve cardiovascular out-
comes in diabetic patients,149,150 mainly by activating
the expression of genes involved in lipid homeostasis.151
PPARa agonists also have the ability to improve renal
lesion in DN animal models; however, whether a similar
efﬁcacy is also observed in diabetic patients remains to
be determined.152 The VDR agonist calcitriol might
ameliorate albuminuria by reducing urinary angio-
tensinogen levels.80 Furthermore, a combination treat-
ment of mineralocorticoid receptor blockers with ACEI
or ARB therapy has recently emerged, but the long-term
efﬁcacy and safety of such treatment has not been
established.153 Although only a few nuclear receptors
were evaluated as potential targets for the treatment of
DN, clinical trials and animal studies have putmore focus
into the function of nuclear hormone receptors for pro-
tection against kidney disease. Identifying the mecha-
nism by which activation of nuclear hormone receptorsKidney International Reports (2016) 1, 177–188modulate kidney disease and determining their roles in
the pathogenesis of DN, and the ultimate application of
nuclear receptor targeting as a therapeutic strategy
require considerably more experimentation.
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